New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond

New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond

Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but also by a non-negligible probability of recurrence and risk progression to muscle-invasive disease. NMIBC management requires a proper local resection and staging, followed by a risk-based treatment with intraves...

Full description

Bibliographic Details
Main Authors: Alessandro Audisio, Consuelo Buttigliero, Marco Donatello Delcuratolo, Elena Parlagreco, Marco Audisio, Antonio Ungaro, Rosario Francesco Di Stefano, Lavinia Di Prima, Fabio Turco, Marcello Tucci
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cells
Subjects:
non-muscle-invasive bladder cancer
BGC-unresponsive
immunotherapy
immune-checkpoint inhibitors
pembrolizumab
Online Access:https://www.mdpi.com/2073-4409/11/3/357

Internet

https://www.mdpi.com/2073-4409/11/3/357

Similar Items